These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Compromised mitochondrial complex II in models of Machado-Joseph disease. Laço MN; Oliveira CR; Paulson HL; Rego AC Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589 [TBL] [Abstract][Full Text] [Related]
4. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100 [TBL] [Abstract][Full Text] [Related]
5. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684 [TBL] [Abstract][Full Text] [Related]
6. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease. Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575 [TBL] [Abstract][Full Text] [Related]
7. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414 [TBL] [Abstract][Full Text] [Related]
15. [Polyglutamine-expanded ataxin-3 is degraded by autophagy]. Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862 [TBL] [Abstract][Full Text] [Related]
16. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007 [TBL] [Abstract][Full Text] [Related]
17. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049 [TBL] [Abstract][Full Text] [Related]
18. Caring for Machado-Joseph disease: current understanding and how to help patients. D'Abreu A; França MC; Paulson HL; Lopes-Cendes I Parkinsonism Relat Disord; 2010 Jan; 16(1):2-7. PubMed ID: 19811945 [TBL] [Abstract][Full Text] [Related]
19. Production of Spinocerebellar Ataxia Type 3 Model Mice by Intravenous Injection of AAV-PHP.B Vectors. Konno A; Shinohara Y; Hirai H Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000316 [TBL] [Abstract][Full Text] [Related]
20. Protective roles of carbonic anhydrase 8 in Machado-Joseph Disease. Hsieh M; Hsieh BY; Ma CY; Li YT; Liu CS; Lo CM J Neurosci Res; 2019 Oct; 97(10):1278-1297. PubMed ID: 31157458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]